Saad Z. Usmani, MD, MBA, FACP, FASCO
Myeloma Specialist & Cellular Therapist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Smoldering or Active Myeloma
- High-Risk Myeloma and Plasma Cell Leukemia
Request an Appointment
About Me
- Chief, Myeloma Service
I am a hematologist-oncologist specializing in the care of patients with multiple myeloma and other disorders affecting plasma cells (the cells that produce the antibodies that protect us against infection). I treat patients who have received a diagnosis of multiple myeloma or a diagnosis of another plasma cell disorder, such as monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, or amyloidosis. Many of the patients I see have a disease that has been deemed hard to treat or high risk.
A blood cancer diagnosis dramatically changes the trajectory of a patient’s life. I am acutely aware of the impact that I have on a patient’s cancer treatment journey and am passionate about having the opportunity to make a difference in my patients’ lives. Throughout my 14-plus years of caring for patients with multiple myeloma and plasma cell disorders, my patients and their family members have always been the most important people in the room for me. It is my responsibility to educate my patients with relevant information about their disease, alleviate their concerns at each stage in the process, and develop a treatment plan that best befits their individual needs. This is not a responsibility that I take lightly. I am committed to making each of my patients feel comforted in the expertise of their care team and empowered by the information provided to them.
Read more
Recent advances in immunotherapy (a type of cancer treatment that uses a patient’s immune system to attack cancer cells in much the same way that it attacks bacteria or viruses) and small molecule therapy are helping to change the outlook for patients with multiple myeloma and other plasma cell disorders. I am excited by the prospect of developing new therapeutic strategies for the treatment and management of these diseases and have been involved with the clinical development of several therapies approved by the FDA for patients with multiple myeloma and other blood cancers.
In addition to novel therapies, my research also centers on the use of minimal residual disease (MRD) testing to guide treatment decisions, developing new approaches for patients with high-risk disease, and establishing methods to recognize patients whose disease will progress from an early precursor disease that does not require treatment to an active disease that does.
Outside of the clinic and the lab, I can likely be found training for a race or an endurance event to raise moneys for cancer research. My most memorable fundraisers so far have been the Mount Everest Base Camp trek in 2018, the Boston Marathon in 2019, and the recently completed 2021 New York City Marathon.
A myeloma specialist is a doctor with special training in diagnosing and treating myeloma.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
My Specialties
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Smoldering or Active Myeloma
- High-Risk Myeloma and Plasma Cell Leukemia
- Other Associated Plasma Cell Disorders
- Multiple Myeloma
- Amyloidosis
- Bone Marrow Transplantation
- Chimeric Antigen Receptor (CAR) T Cell Therapy
- Bispecific Antibodies
- Immunotherapy
Education
- MBBS, Allama Iqbal Medical College
Residencies
- Internal Medicine - Sinai-Grace Hospital/Wayne State University
Awards and Honors
- Board Member of the International Myeloma Society (2023)
- LLS Scholar in Clinical Research Award (2017-2022)
- Celgene Young Investigator Award for Clinical Research in Hematology (2018)
- Vice-Chair, ASH Scientific Committee on Plasma Cell Neoplasia (2019)
- Chair, ASCO Educational Program Committee on Plasma Cell Disorders (2019)
- Chair, ASH Scientific Committee on Plasma Cell Neoplasia (2020)
- Chair, ASCO Educational Program Committee on Plasma Cell Disorders (2021)
- Vice-Chair, SWOG Barlogie-Salmon Myeloma Committee (2020-present)
- Multiple Myeloma Excellence in Clinical Research Award, COMy Congress (2020)
- Bart Barlogie Young Investigator Award in Clinical and Translational Research, 18th International Myeloma Workshop, Vienna, Austria (2021)
- Career Development Achievement Award, The Leukemia & Lymphoma Society (2022)
- Chair, ALLIANCE Myeloma Committee (2022-present)
- Fellow, Royal College of Physicians UK (2023-present)
- Board Member, International Myeloma Society (2023-2027)
- Fellow, American Society of Clinical Oncology (2024-present)
Fellowships
- Hematology & Medical Oncology - University of Connecticut Health Center
Board Certifications
- ABIM Internal Medicine, Hematology & Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, HMO
MSK has a tentative agreement with Cigna to continue coverage in 2024.
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Usmani sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Usmani
- A Phase 1 Study of ABBV-453 in People with Recurrent or Persistent Multiple Myeloma
- A Phase 1 Study of KTX-1001 in People With Multiple Myeloma
- A Phase 1b/2 Study of Talquetamab and Teclistamab in People With Multiple Myeloma
- A Phase 2 Study of Leflunomide in African-American and European-American People with High-Risk Smoldering Multiple Myeloma
Read more
- A Phase 3 Study Comparing VRd (Bortezomib, Lenalidomide, and Dexamethasone) Followed by Cilta-Cel CAR T Cell Therapy versus VRd Followed by Rd (Lenalidomide and Dexamethasone) in People with Multiple Myeloma
- A Phase IB Study of Cetrelimab plus Talquetamab or Teclistamab in People with Multiple Myeloma
- A Phase IB/IIA Study of CC-92480 in Combination with Other Anticancer Drugs in People with Multiple Myeloma
- Clinical Trials Co-Investigated by Dr. Usmani
- A Phase 1 Study of BMS-986393 CAR T Cell Therapy in People With Multiple Myeloma
- A Phase 1 Study of CB-011 CAR T Cell Therapy in People With Multiple Myeloma
- A Phase 1/2 Study of BGB-11417 Given Alone and With Carfilzomib and/or Dexamethasone to Treat Multiple Myeloma
- A Phase I Study of MCARH109 and MCARH125 CAR T-Cell Therapy in People with Multiple Myeloma
- A Study of Talquetamab for People With Multiple Myeloma Who Had CAR T Cell Therapy
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Read more
Visit PubMed for a full listing of Dr. Usmani’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Saad Z. Usmani discloses the following relationships and financial interests:
-
AbbVie
Professional Services and Activities -
Bristol-Myers Squibb
Professional Services and Activities -
Genzyme
Professional Services and Activities -
GlaxoSmithKline
Professional Services and Activities -
Gracell Biotechnologies Ltd.
Professional Services and Activities
-
Janssen Biotech, Inc.
Professional Services and Activities -
Merck & Co Inc.
Professional Services and Activities -
Novartis
Professional Services and Activities -
Pfizer, Inc.
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
